Granted Patent
B2
US 9,594,083 · App. 14/426,563 · Granted Mar 14, 2017
Method for the treatment of cardiovascular fibrosis
Inventors:
Frederic Jaisser (Paris, FR); Nicolette Farman (Paris, FR); Antoine Tarjus (Paris, FR); Patrick Rossignol (Vandoeuvre-les-nancy, FR); Faiez Zannad (Vandoeuvre-les-nancy, FR)
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale); Universite de Lorraine; Cantre Hospitalier et Universitaire de Nancy (CHU); Universite Paris Diderot-Paris 7; Universite Paris Descartes
G01N33/573A61K31/7088A61K31/713A61K31/7105C07K14/47C12N15/113C12N15/115C12N2310/11C12N2310/14G01N2500/04G01N2800/325
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
Claims (1)
1. A method for treating cardiovascular fibrosis induced by aldosterone in a subject at risk of developing heart failure, comprising administering to the subject a therapeutically effective amount of an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) expression, wherein inhibition of NGAL expression inhibits progression of cardiovascular fibrosis to heart failure.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 6, 2015
From: JAISSER, FREDERIC; FARMAN, NICOLETTE; TARJUS, ANTOINE; ROSSIGNOL, PATRICK; ZANNAD, FAIEZ
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; UNIVERSITE DE LORRAINE; CENTER HOSPITALIER ET UNIVERSITAIRE DE NANCY (CHU); UNIVERSITE PARIS DIDEROT PARIS-7; UNIVERSITE PARIS DESCARTES
Reel/Frame 035104/0191 →
Priority Claims (1)
EP 12306178
· Sep 28, 2012
· regional
Continuity (1)